[{"AccountsPayableCurrent_0_Q2_USD":4603000.0,"BusinessAcquisitionProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTaxPerShareBasic_1_Q2_USD":-0.12,"BusinessAcquisitionProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTaxPerShareDiluted_2_Q2_USD":-0.23,"BusinessAcquisitionProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTaxPerShareDiluted_1_Q2_USD":-0.12,"BusinessAcquisitionsProFormaNetIncomeLoss_2_Q2_USD":-2500000.0,"BusinessAcquisitionsProFormaNetIncomeLoss_1_Q2_USD":-1327000.0,"BusinessAcquisitionsProFormaRevenue_2_Q2_USD":23015000.0,"BusinessAcquisitionsProFormaRevenue_1_Q2_USD":11671000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-408000.0,"BusinessAcquisitionProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTaxPerShareBasic_2_Q2_USD":-0.23,"ContractWithCustomerLiability_0_Q2_USD":10869000.0,"FinanceLeaseInterestExpense_1_Q2_USD":68000.0,"FinanceLeaseInterestPaymentOnLiability_2_Q2_USD":75000.0,"FinanceLeaseInterestPaymentOnLiability_1_Q2_USD":43000.0,"FinanceLeaseLiability_0_Q2_USD":4662000.0,"FinanceLeaseLiabilityCurrent_0_Q2_USD":4602000.0,"FinanceLeaseLiabilityPaymentsDue_0_Q2_USD":4736000.0,"FinanceLeaseLiabilityPaymentsDueAfterYearFive_0_Q2_USD":0.0,"FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":4670000.0,"FinanceLeaseInterestExpense_2_Q2_USD":134000.0,"FinanceLeaseLiabilityPaymentsDueYearFive_0_Q2_USD":8000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":123000.0,"IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2_Q2_shares":0.0,"SellingExpense_1_Q2_USD":1098000.0,"EarningsPerShareDiluted_2_Q2_USD":-0.19,"EarningsPerShareDiluted_1_Q2_USD":-0.05,"FinanceLeaseLiabilityNoncurrent_0_Q2_USD":60000.0,"InventoryValuationReserves_0_Q2_USD":203000.0,"NetIncomeLossAvailableToCommonStockholdersDiluted_2_Q2_USD":-2014000.0,"NetIncomeLossAvailableToCommonStockholdersDiluted_1_Q2_USD":-588000.0,"ProceedsFromLongTermLinesOfCredit_2_Q2_USD":1329000.0,"IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1_Q2_shares":0.0,"ProceedsFromLinesOfCredit_2_Q2_USD":24263000.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":3791000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":204000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":123000.0,"FairValueOfAssetsAcquired_2_Q2_USD":6435000.0,"ProceedsFromIssuanceOfDebt_2_Q2_USD":3533000.0,"IncrementalCommonSharesAttributableToConversionOfPreferredStock_2_Q2_shares":0.0,"IncrementalCommonSharesAttributableToConversionOfPreferredStock_1_Q2_shares":0.0,"LiabilitiesAssumed1_2_Q2_USD":1302000.0,"RepaymentsOfLinesOfCredit_2_Q2_USD":22711000.0,"SellingExpense_2_Q2_USD":1980000.0,"FinanceLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":13000.0,"FinanceLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":30000.0,"OperatingLeaseCost_1_Q2_USD":215000.0,"OperatingLeaseLiability_0_Q2_USD":4755000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":859000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":3896000.0,"OperatingLeasePayments_2_Q2_USD":138000.0,"OperatingLeasePayments_1_Q2_USD":80000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":4507000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.0522,"OperatingLeaseCost_2_Q2_USD":429000.0,"ProceedsFromConstructionLoansPayable_2_Q2_USD":1089000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_Q2_USD":448000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1_Q2_USD":71000.0,"ShortTermLeaseCost_2_Q2_USD":21000.0,"ShortTermLeaseCost_1_Q2_USD":7000.0,"SubleaseIncome_2_Q2_USD":318000.0,"SubleaseIncome_1_Q2_USD":159000.0,"TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense_2_Q2_USD":1648000.0,"UnamortizedDebtIssuanceExpense_0_Q2_USD":281000.0,"RestructuringReserveCurrent_0_Q2_USD":225000.0,"FinanceLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":15000.0,"NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_2_Q2_USD":4000000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":769000.0,"FinanceLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":74000.0,"FinanceLeasePrincipalPayments_2_Q2_USD":79000.0,"FinanceLeasePrincipalPayments_1_Q2_USD":42000.0,"FinanceLeaseRightOfUseAsset_0_Q2_USD":4668000.0,"FinanceLeaseRightOfUseAssetAmortization_2_Q2_USD":75000.0,"FinanceLeaseRightOfUseAssetAmortization_1_Q2_USD":43000.0,"FinanceLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.0599,"ForeignCurrencyTransactionGainLossUnrealized_2_Q2_USD":-5000.0,"LiabilityForUncertainTaxPositionsCurrent_0_Q2_USD":0.0,"IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_2_Q2_USD":102000.0,"LeaseCost_1_Q2_USD":175000.0,"LeaseIncentiveReceivableNoncurrent_0_Q2_USD":132000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":5524000.0,"LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0_Q2_USD":442000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0_Q2_USD":1343000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":964000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":981000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":905000.0,"LeaseCost_2_Q2_USD":343000.0,"RepaymentsOfLongTermDebt_2_Q2_USD":603000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":20000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q2_USD":-588000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-7351000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":213000.0,"NetIncomeLoss_2_Q2_USD":-2014000.0,"NetIncomeLoss_1_Q2_USD":-588000.0,"ProfitLoss_1_Q2_USD":-588000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":27731000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-19239000.0,"Revenues_2_Q2_USD":28930000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":6730000.0,"Revenues_1_Q2_USD":16012000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":2316000.0,"CommonStockSharesAuthorized_0_Q2_shares":19000000.0,"DepreciationAndAmortization_2_Q2_USD":1673000.0,"EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_Q2_pure":0.21,"InterestExpense_2_Q2_USD":703000.0,"InterestExpense_1_Q2_USD":392000.0,"InterestPaidNet_2_Q2_USD":494000.0,"OperatingExpenses_2_Q2_USD":9885000.0,"StockholdersEquity_0_Q2_USD":9925000.0,"OperatingExpenses_1_Q2_USD":5388000.0,"LiabilitiesCurrent_0_Q2_USD":29047000.0,"Liabilities_0_Q2_USD":51743000.0,"AccountsReceivableNetCurrent_0_Q2_USD":9109000.0,"AdditionalPaidInCapital_0_Q2_USD":26451000.0,"Assets_0_Q2_USD":61668000.0,"AssetsCurrent_0_Q2_USD":15503000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":198000.0,"CommonStockSharesIssued_0_Q2_shares":10864281.0,"CommonStockSharesOutstanding_0_Q2_shares":10864281.0,"CommonStockValue_0_Q2_USD":2678000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":61668000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":7581000.0,"GrossProfit_2_Q2_USD":8670000.0,"GrossProfit_1_Q2_USD":5193000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":108000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":11000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-577000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":1873000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":723000.0,"InventoryNet_0_Q2_USD":1204000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":4128000.0,"OperatingIncomeLoss_2_Q2_USD":-1215000.0,"OperatingIncomeLoss_1_Q2_USD":-195000.0,"PreferredStockValue_0_Q2_USD":35000.0,"CostOfGoodsAndServicesSold_1_Q2_USD":10819000.0,"EarningsPerShareBasic_2_Q2_USD":-0.19,"EarningsPerShareBasic_1_Q2_USD":-0.05,"Goodwill_0_Q2_USD":4368000.0,"LongTermDebt_0_Q2_USD":20854000.0,"LongTermDebtNoncurrent_0_Q2_USD":18650000.0,"OtherAssetsNoncurrent_0_Q2_USD":153000.0,"PaymentsOfDebtIssuanceCosts_2_Q2_USD":111000.0,"CostOfGoodsAndServicesSold_2_Q2_USD":20260000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":10756000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":-422000.0,"PaymentsToAcquireBusinessesGross_2_Q2_USD":3351000.0,"StockIssued1_2_Q2_USD":1133000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_Q2_USD":-1906000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1_Q2_USD":-577000.0,"CommonStockNoParValue_0_Q2_USD":0.0,"LongTermDebtCurrent_0_Q2_USD":1923000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_2_Q2_USD":-2014000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":10843000.0,"PrepaidExpenseCurrent_0_Q2_USD":1901000.0,"PaymentsForProceedsFromProductiveAssets_2_Q2_USD":4000000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":10000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":324000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":162000.0,"ShareBasedCompensation_2_Q2_USD":204000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_Q2_pure":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_Q2_pure":0.0161,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":20000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":10756000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":10843000.0,"AllowanceForDoubtfulAccountsReceivableCurrent_0_Q2_USD":493000.0,"DeferredIncomeTaxLiabilitiesNet_0_Q2_USD":90000.0,"EffectiveIncomeTaxRateContinuingOperations_2_Q2_pure":0.0594,"IncreaseDecreaseInInventories_2_Q2_USD":109000.0,"InventoryFinishedGoods_0_Q2_USD":378000.0,"InventoryGross_0_Q2_USD":1407000.0,"InventoryRawMaterials_0_Q2_USD":851000.0,"InventoryWorkInProcess_0_Q2_USD":178000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":889000.0,"OtherIntangibleAssetsNet_0_Q2_USD":4606000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":12000.0,"VariableLeaseCost_2_Q2_USD":2000.0,"VariableLeaseCost_1_Q2_USD":1000.0,"Ticker":"NOTV","CIK":"720154","name":"BIOANALYTICAL SYSTEMS INC","OfficialName":"Inotiv Inc. Common Stock","form":"10-Q","period":"20200331","fy":"2020.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"611279258.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200514"}]